Titre:
  • Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
Auteur:Harbeck, Nadia; Jassem, Jacek; Zhang, Qingyuan; Im, Young Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer Georg; Uttenreuther-Fischer, Martina; Xu, Binghe; Piccart-Gebhart, Martine; Huang, Chiun Sheng; Hurvitz, Sara; Yeh, Dah Cherng; Shao, Zhimin; Im, Seock Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil
Informations sur la publication:Lancet oncology, 17, 3, page (357-366)
Statut de publication:Publié, 2016-03
Sujet CREF:Cancérologie
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(15)00540-9
info:pii/S1470204515005409
info:scp/84960496215